Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Open access
Fendler, Wolfgang P., Reinhardt, Svenja, Ilhan, Harun, Delker, Andreas, Böning, Guido, Gildehaus, Franz J., Stief, Christian, Bartenstein, Peter, Gratzke, Christian, Lehner, Sebastian, Rominger, Axel · 2017 · Oncotarget

Abstract

// Wolfgang P. Fendler 1,2 , Svenja Reinhardt 1 , Harun Ilhan 1 , Andreas Delker 1 , Guido Böning 1 , Franz J. Gildehaus 1 , Christian Stief 3,4 , Peter Bartenstein 1,4 , Christian Gratzke 3,4 , Sebastian Lehner 1 and Axel Rominger 1 1 Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany 2 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA 3 Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany 4 Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany Correspondence to: Wolfgang P. Fendler, email: // Keywords : mCRPC; PET; prostate cancer; PSMA; lutetium Received : March 20, 2016 Accepted : September 19, 2016 Published : September 24, 2016 Abstract Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifteen patients each received two cycles of 3.7 GBq ( n = 5) or 6.0 GBq ( n = 10) 177 Lu-PSMA-617 at an eight to ten weeks interval. For safety monitoring, each treatment was followed by dosimetry with serial quantitative SPECT as well as inpatient and outpatient recording of adverse events. Response to RLT was primarily determined by baseline to follow-up change in 68 Ga-PSMA PET/CT (RECIST1.1), as well as change in prostate-specific antigen (PSA), quality of life (QoL, FACT-P scale), and pain (Brief Pain Inventory) as secondary endpoints. Radiation dose delivered to the tumor (6.1 Gy/GBq) was six to twelve-fold higher than to critical organs (kidney left/right 0.5/0.6 Gy/GBq each, salivary glands 1.0 Gy/GBq). Total radiation dose per kidney did not exceed 23 Gy in any patient. Three patients had sub-acute and latent grade 3 events, i.e. anemia, leukocytopenia, and nausea. No acute events, grade ≥4 events or high grade events for salivary gland or kidney function were observed. After two RLT cycles, 4 (27%) patients had partial response, 6 (40%) had stable disease, and 5 (33%) had progressive disease according to RECIST. Any PSA decline was observed in 12/15 (80%) patients during RLT. Significant pain relief was documented in 7/10 (70%) symptomatic patients and QoL improved in 9/15 (60%) patients. 177 Lu-PSMA-617 therapy proved safe and indicated promising response rates for both objective and patient-reported outcomes in our small group of mCRPC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12240

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 223

Metadata

Authors
Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C., Bartenstein, P., Gratzke, C., Lehner, S., & Rominger, A.
Venue
Oncotarget
Published
2016-09-24
Volume
8
Issue
2
Pages
3581-3590
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2523333323
Cited by
223
References
7
FWCI
17.61
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.